A clinical observational study for Xin-Guan-2 formula in the treatment of suspected novel coronavirus pneumonia (COVID-19)
Phase 1
- Conditions
- novel coronavirus pneumonia (COVID-19)
- Registration Number
- ITMCTR2000002978
- Lead Sponsor
- Guangdong Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients who meet the diagnostic criteria of suspected cases of pneumonia caused by novel coronavirus infection.
Exclusion Criteria
An allergic condition, such as a history of allergies to two or more drugs or foods, or a known allergy to the ingredients in Xin-Guan-2 formula.
Study & Design
- Study Type
- Observational study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to completely antipyretic time:completely antipyretic was defined as the body temperature return to normal for over 24 hours.;Main symptom relief/disappearance time: defined as the days when the three main symptoms of fever, cough and shortness of breath all remission/disappear.;
- Secondary Outcome Measures
Name Time Method iver and kidney function;The incidence of medical complications during isolation;Length of hospital stay;C-reactive protein;Proportion of good clinical response patients;Routine blood test;